In a November 12th presentation at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS @ AAO) in Las Vegas, Nev., PanOptica President and CEO Paul G. Chaney reported progress with the clinical development program for PAN-90806, a clinical-stage candidate as a topical anti-vascular endothelial growth factor (anti-VEGF) eyedrop for the treatment of neovascular eye diseases, including preliminary results from the monotherapy arm of a Phase 1/2 study showing signals of safety and anti-VEGF biological activity in patients with wet AMD.

“Neovascular eye diseases frequently require continuous, life-long treatment in order to attain optimal efficacy.  A safe and effective topical anti-VEGF eyedrop would reduce the treatment burden associated with current therapies, potentially eliminate injection-related risks, and would also be compatible with the growing number of combination therapies for AMD and diabetic macular edema,” noted Elias Reichel, M.D., Professor and Vice Chair for Research and Education in the Department of Ophthalmology at the New England Eye Center in Boston, Massachusetts.

Mr. Chaney presented preliminary Phase 1/2 results in which signals of anti-VEGF biological activity were observed across all PAN-90806 monotherapy dose arms in patients with wet AMD, including at the lowest doses. Those signals were confirmed independently by a focus panel of retina experts. He noted that safety assessments of PAN-90806 are ongoing, and that no treatment-related systemic adverse events (AEs) have been reported to date; safety signals thus far have been limited to ocular surface findings at higher doses.

Further information: http://www.businesswire.com/news/home/20151112005385/en/PanOptica-Reports-Progress-PAN-90806-Topical-Anti-VEGF-Eyedrop